Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in ...

Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company focused on developing and commercializing novel therapies for difficult-to-treat cancers, has demonstrated resilience and growth potential in ...

Researchers identified the enzyme CMPK2 as a possible target for therapies aiming to prevent metabolic dysfunction-associated ...

YOUR home should be a safe place. But when it comes to your cancer risk, potentially harmful products could be posing a ...

Discover how alcohol consumption exacerbates the risk of cirrhosis and hepatocellular carcinoma by promoting hepatitis B virus replication and weakening immunity.

Maxim analyst Jason McCarthy upgraded NAYA Biosciences (NAYA) to Buy from Hold with a $2 price target The firm is positive on the company’s ...

Hepion Pharmaceuticals has had a turbulent year so far. With a YTD performance of -68.60%, its stock has struggled to gain traction in the market. This starkly contrasts with the broader market, as ...